March 16, 2017
The Central Social Insurance Medical Council (Chuikyo) approved on March 15 optimal use promotion guidelines for the PCSK9 inhibitors Repatha (evolocumab) and Praluent (alirocumab). The Ministry of Health, Labor and Welfare (MHLW) issued “points to note” notification letters that restricted...read more